{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248137","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.803107+00:00","generated_at":"2026-05-30T07:17:21.968254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%","bullets":["Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.","Cash, equivalents, and marketable securities $1.0B at Sep 30, 2024.","Operating expenses $178.5M vs $98.5M YoY; SG&A $107.6M driven by commercial launch.","Commercial coverage achieved for >80% of lives; <5% require biopsy for diagnosis.","Completed enrollment in MAESTRO-NASH OUTCOMES trial for compensated NASH cirrhosis; EMA decision mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248137","json":"https://secwatch.observer/filing/0001193125-24-248137.json","markdown":"https://secwatch.observer/filing/0001193125-24-248137.md","text":"https://secwatch.observer/filing/0001193125-24-248137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524248137/0001193125-24-248137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524248137/d788088d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:17:21.968254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}